Results 71 to 80 of about 1,145,786 (286)
Ki-67 in meningioma: distribution and implications
Journal of NeurosurgeryOBJECTIVE Ki-67 is a widely used marker of proliferation in meningiomas, influencing prognostic assessment and treatment decisions, including adjuvant radiation therapy. However, it is increasingly appreciated that some meningiomas are enriched with immune infiltration, which may confound Ki-67 interpretation as
Xiaopeng, Guo +4 more
openaire +2 more sources
Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li +10 more
wiley +1 more source
Transplant associated SCC (TSCC) shows diffuse Ki-67 staining and increased numbers of Ki-67+ cells. [PDF]
, 2013 Representative immunohistochemistry at (a) 10X and (b) 20X, with (c) mean cell count values of Ki-67+ cells in SCC (n = 5) and TSCC (n = 5). T indicates tumor. Only cells along or within tumors were counted.
Diane Felsen (410232) +11 more
core +1 more source
Scientific ReportsThe objective of this study was to evaluate the correlation between positron emission tomography/computed tomography (PET/CT) parameters and the degree of proliferation of lung adenocarcinoma. A retrospective analysis was conducted on 50 patients who had
Jian-gong Shi +4 more
doaj +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases [PDF]
, 2013 Breast cancer can recur even decades after the primary therapy. Markers are needed to predict cancer progression and the risk of late recurrence. The estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2 ...
Marjut Leidenius +5 more
core +1 more source
Imaging characteristics of central neurocytomas according to Ki-67 proliferation index
Frontiers in OncologyPurposeTo evaluate the imaging characteristics of central neurocytoma (CN) with different Ki-67 indices and reveal its biological behavior.Materials and methodsSixty-nine cases of intraventricular CN confirmed by histopathology were collected ...
Yan-li Zhang +4 more
doaj +1 more source
Ki-67 expression in squamous intraepithelial lesions of the uterine cervix [PDF]
Archive of Oncology, 2006 BACKGROUND: Uncontrolled cell proliferation and malignant transformation are the basic elements in the development of malignant disease including cervical cancer and its precursors.
Panjković Milana +1 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec +6 more
wiley +1 more source
Immunostaining of Ki-67 and CDK1. [PDF]
, 2019 Immunohistochemical analysis of Ki-67 and CDK1 expression in aortic dissection (n = 5) and control tissue samples (n = 5). A: Strong Ki-67 expression on aortic dissection tissue. B: Weak Ki-67 expression on control tissue.
Weitie Wang (5381612) +9 more
core +1 more source